Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma-Reference-Cited by-同舟云学术

Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma

Published:2018-11 Issue:11 Volume:36 Page:499.e9-499.e16
ISSN:1078-1439
Container-title:Urologic Oncology: Seminars and Original Investigations
language:en
Short-container-title:Urologic Oncology: Seminars and Original Investigations

Author:

Ueda Kosuke^ORCID,Suekane Shigetaka,Kurose Hirofumi,Chikui Katsuaki,Nakiri Makoto,Nishihara Kiyoaki,Matsuo Mitsunori,Kawahara Akihiko,Yano Hirohisa,Igawa Tsukasa

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference37 articles.

1. Novel agents and approaches for advanced renal cell carcinoma;Figlin;J Urol,2012

2. Nivolumab versus everolimus in advanced renal-cell carcinoma;Motzer;N Engl J Med,2015

3. Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study;Tomita;Jpn J Clin Oncol,2017

4. The blockade of immune checkpoints in cancer immunotherapy;Pardoll;Nat Rev Cancer,2012

5. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death;Ishida;EMBO J,1992

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Personalized treatment using predictive biomarkers in solid organ malignancies: A review;Tumori Journal;2024-08-02

2. PD1/PD-L1 blockade in clear cell renal cell carcinoma: mechanistic insights, clinical efficacy, and future perspectives;Molecular Cancer;2024-07-16

3. Immune cells and checkpoints in pancreatic adenocarcinoma: Association with clinical and pathological characteristics;PLOS ONE;2024-07-02

4. The two types of immune microenvironment of renal cancer;Russian Journal of Biotherapy;2024-06-26

5. miR-4429 inhibits ccRCC proliferation, migration, and invasion by directly targeting CD274;Discover Oncology;2024-05-27